Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Total revenues	$ 68,556	$ 74,205	$ 86,180
Operating expenses:
Cost of revenue	26	845	2,765
Research and development	455,966	506,499	579,720
Selling, general and administrative	92,074	119,031	174,441
Restructuring, long-lived assets impairment and related charges, net	(182)	34,995	13,559
Total operating expenses	547,884	661,370	770,485
Loss from operations	(479,328)	(587,165)	(684,305)
Other income:
Change in fair value of equity investments	1,729	(5,528)	(21,888)
Interest income	40,238	71,809	86,990
Other expense, net	(409)	(2,221)	(8,991)
Total other income	41,558	64,060	56,111
Loss before (provision for) benefit from income taxes	(437,770)	(523,105)	(628,194)
(Provision for) benefit from income taxes	(217)	1,145	13,077
Net loss	(437,987)	(521,960)	(615,117)
Net loss attributable to noncontrolling interest	0	0	(56)
Net loss attributable to Vir Bio	$ (437,987)	$ (521,960)	$ (615,061)
Net loss per share attributable to VirBio, basic (in USD per share)	$ (3.16)	$ (3.83)	$ (4.59)
Net loss per share attributable to VirBio, diluted (in USD per share)	$ (3.16)	$ (3.83)	$ (4.59)
Weighted-average shares outstanding, basic (in shares)	138,520,419	136,246,865	134,130,924
Weighted-average shares outstanding, diluted (in shares)	138,520,419	136,246,865	134,130,924
License and collaboration revenue
Revenues:
Total revenues	$ 63,130	$ 61,370	$ 37,382
Grant revenue
Revenues:
Total revenues	2,036	10,493	46,686
Other revenue
Revenues:
Total revenues	$ 3,390	$ 2,342	$ 2,112